ZA200710611B - New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases - Google Patents

New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases

Info

Publication number
ZA200710611B
ZA200710611B ZA200710611A ZA200710611A ZA200710611B ZA 200710611 B ZA200710611 B ZA 200710611B ZA 200710611 A ZA200710611 A ZA 200710611A ZA 200710611 A ZA200710611 A ZA 200710611A ZA 200710611 B ZA200710611 B ZA 200710611B
Authority
ZA
South Africa
Prior art keywords
treatment
receptor antagonists
gastrointestinal diseases
neurokinin receptor
azetidine derivatives
Prior art date
Application number
ZA200710611A
Other languages
English (en)
Inventor
Holmqvist Sara
Svensson Arne
Johansson Anders
Von Unge Sverker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200710611B publication Critical patent/ZA200710611B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200710611A 2005-06-23 2007-12-05 New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases ZA200710611B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0501494 2005-06-23

Publications (1)

Publication Number Publication Date
ZA200710611B true ZA200710611B (en) 2008-11-26

Family

ID=37570728

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200710611A ZA200710611B (en) 2005-06-23 2007-12-05 New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases

Country Status (12)

Country Link
US (1) US20100069346A1 (xx)
EP (1) EP1899326A4 (xx)
JP (1) JP2009501144A (xx)
KR (1) KR20080036957A (xx)
CN (1) CN101203511A (xx)
AU (1) AU2006259891A1 (xx)
CA (1) CA2612133A1 (xx)
IL (1) IL187966A0 (xx)
MX (1) MX2007015606A (xx)
NO (1) NO20080445L (xx)
WO (1) WO2006137790A1 (xx)
ZA (1) ZA200710611B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
WO2007136325A1 (en) * 2006-05-18 2007-11-29 Astrazeneca Ab 1- [ (4- [benzoyl (methyl) amino] -3- (phenyl) butyl] azetidine derivatives for the treatment of gastrointestinal disorders 2
US8106208B2 (en) * 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
WO2007136326A2 (en) * 2006-05-18 2007-11-29 Astrazeneca Ab ) t e text as een esta s e y t s ut o ty to rea as o ows: 1- [ (4- [benzoyl (methyl) amino] -3- (phenyl) butyl] azetidine derivatives for the treatment of gastrointestinal disorders 3
KR101558005B1 (ko) * 2007-03-08 2015-10-06 알비레오 에이비 2-치환-3-페닐프로피온산 유도체 및 염증성 장 질환 치료에서의 그의 용도
WO2008118092A1 (en) * 2007-03-28 2008-10-02 Albireo Ab Maleate salt of 3-bromo-n-{ (2s) -2- (4-f luorophenyl) -4- [3- (4-acetylpiperazin-1-yl) azetidin-1-yl] butyl} -methyl-5- (trifluoromethyl)benzamide for the treatment of gastrointestinal disorders
WO2008118091A1 (en) * 2007-03-28 2008-10-02 Albireo Ab A fumarate salt of 3-bromo-n-{ (2s) -2- (4 -fluorophenyl) -4- [3- (4-acetylpiperazin-l-yl) azetidin-1-yl] butyl} -n-methyl-5- (trifluoromethyl)benzamide for the treatment of gastrointestinal disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102459166B (zh) * 2009-04-22 2015-03-25 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的氮杂环丁烷基二酰胺
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
CN105663133B (zh) * 2016-03-07 2019-06-25 青岛市肿瘤医院 一种抑制淋巴瘤细胞增殖的药物组合物及其应用
ES2970361T3 (es) 2019-05-24 2024-05-28 Irl 790 Ab Sales de ácido tartárico de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propil)amina
EP4243801A1 (en) 2020-11-10 2023-09-20 Integrative Research Laboratories Sweden AB [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
GB9601202D0 (en) * 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
IL140770A0 (en) * 1998-07-10 2002-02-10 Astrazeneca Ab N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
GB9922519D0 (en) * 1998-10-07 1999-11-24 Zeneca Ltd Compounds
TW200508221A (en) * 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds

Also Published As

Publication number Publication date
EP1899326A1 (en) 2008-03-19
IL187966A0 (en) 2008-03-20
CN101203511A (zh) 2008-06-18
MX2007015606A (es) 2008-02-25
WO2006137790A1 (en) 2006-12-28
CA2612133A1 (en) 2006-12-28
JP2009501144A (ja) 2009-01-15
AU2006259891A1 (en) 2006-12-28
NO20080445L (no) 2008-01-23
US20100069346A1 (en) 2010-03-18
KR20080036957A (ko) 2008-04-29
EP1899326A4 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
IL187966A0 (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
EP1899318A4 (en) NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
IL185422A0 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL195571A0 (en) Compounds for the treatment of periodontal disease
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
TWI369987B (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
IL191283A (en) Compositions for treating eye irregularities
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
EP1833467A4 (en) PHARMACEUTICAL COMPOSITIONS FOR SLEEP DISORDERS
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
IL180680A0 (en) Piperazine derivatives useful for the treatment of gastrointestinal disorders
IL186188A0 (en) Pyrimidindione derivatives as prokineticin 2 receptor antagonists
HK1119577A1 (en) Compounds for the treatment of metabolic disorders
IL190652A0 (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
PL2418201T3 (pl) Polimorficzne postaci p-hydroksybeznoesanu (2S)-(4E)-N-metylo-5-[3-(5-izopropoksypirydyn)ylo]-4-penteno-2-aminy do leczenia zaburzeń ośrodkowego układu nerwowego
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
IL188856A0 (en) Novel piperidine derivatives as chemokine receptor modulators useful for the treatment of respiratory diseases
ZA200805159B (en) Imidazole derivatives for the treatment of gastrointestinal disorders
PL1833821T3 (pl) Sulfamidy jako antagoniści receptora endoteliny do leczenia chorób układu sercowo-naczyniowego
ZA200802339B (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
HU0500145D0 (en) Composition for the treatment of oral diseases
ZA200900613B (en) 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonist for the treatment of CNS disorders
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
GB0400802D0 (en) Compounds for the treatment of disease